Navigation Links
Gladstone scientists uncover potential mechanism of memory loss in Alzheimer's disease
Date:9/5/2007

SAN FRANCISCO, CA -- September 6, 2007 -- Researchers at the Gladstone Institute of Neurological Disease (GIND) and Baylor College of Medicine have discovered a mechanism by which the protein Amyloid-beta(AB) may impair neurological functions in Alzheimer's disease. AB, which is known to accumulate in the brains of Alzheimer patients, has long been a focus of research into the causes and treatment of the disease. In a study published in the journal Neuron, Gladstone scientists found that A-beta triggers abnormal overexcitation of the very brain networks that are responsible for learning and memory.

"Such abnormal network activity in Alzheimer's patients was thought to be a collateral or secondary event caused by the degeneration of nerve cells," said Jorge J Palop, PhD, Gladstone research scientist and lead author of the study. "But our study suggests that this activity may actually be a primary effect of A-beta and an early determinant of cognitive failure."

The Gladstone team used several genetically engineered mouse models of AD in which memory deficits are triggered by a human gene that causes high levels of A-beta. They discovered that high levels of A-beta induce an insidious type of seizure activity in learning and memory centers that is not accompanied by the usual twitching and jerking movements seen in many forms of epilepsy. In fact, it took sophisticated brain wave recordings in freely behaving mice by electroencephalography (EEG) and telemetry to detect the seizure activity.

"We were really surprised by these findings because A-beta had previously been suspected to primarily suppress neuronal activity," said Lennart Mucke, MD, GIND director and professor of neurology and neuroscience at the University of California, San Francisco (UCSF), and senior author of the study. "This abnormal brain activity could play an important role in the development of Alzheimer-related cognitive impairments."

Physicians have long recognized that Alzheimer patients have a higher incidence of convulsive seizures than reference populations. The new study indicates that A-beta is to blame for this problem and raises the disconcerting possibility that these patients may also have non-convulsive seizures that could easily escape detection by standard clinical exams. The investigators are eager to test this hypothesis in a planned follow-up study of human subjects.

"Our results have important therapeutic implications, because the prevention and reversal of non-convulsive seizure activity has not yet been a major focus of clinical trials in Alzheimer's disease. Our results suggest that the suppression of this activity might prevent and possibly even reverse cognitive impairments induced by high levels of A-beta," said Dr. Mucke.


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Related biology technology :

1. UW computer scientists fighting computer virus "Cold War"
2. Scientists find way to make human collagen in lab
3. Wisconsin scientists to be recognized for innovative biofuel technology
4. UW-Madison scientists to mimic nature for newest cancer drugs
5. UW scientists study strange material with communications potential
6. Scientists find nanotech method for examining cells
7. UW space scientists use Keck telescope to study wild weather of Uranus
8. UW computer scientists tout achievements and explain industry shortcomings
9. Facing shortage of U.S. scientists, UW wants to boost math enrollment
10. UW-Madison scientists find a key to cell division
11. TIP/UW Scientists Provide Mars Rover Commentary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Who risk to ... Download the full report: https://www.reportbuyer.com/product/4313699/ ... FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
Breaking Biology News(10 mins):